1. Home
  2. IZM vs PPCB Comparison

IZM vs PPCB Comparison

Compare IZM & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICZOOM Group Inc.

IZM

ICZOOM Group Inc.

SELL

Current Price

$0.95

Market Cap

2.3M

ML Signal

SELL

Logo Propanc Biopharma Inc.

PPCB

Propanc Biopharma Inc.

BUY

Current Price

$0.39

Market Cap

2.6M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
IZM
PPCB
Founded
2011
2007
Country
China
Australia
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.3M
2.6M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
IZM
PPCB
Price
$0.95
$0.39
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.1M
156.4K
Earning Date
10-27-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.39
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.06
52 Week High
$2.73
$6.79

Technical Indicators

Market Signals
Indicator
IZM
PPCB
Relative Strength Index (RSI) 51.14 28.71
Support Level $0.28 $0.17
Resistance Level $1.46 $0.40
Average True Range (ATR) 0.19 0.05
MACD -0.05 0.01
Stochastic Oscillator 11.56 6.67

Price Performance

Historical Comparison
IZM
PPCB

About IZM ICZOOM Group Inc.

ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.

About PPCB Propanc Biopharma Inc.

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Share on Social Networks: